ADOCIA Reports First Quarter 2024 Financial Results and Provides a Business Update

LYON, France--(BUSINESS WIRE)-- #BIOTECH--Regulatory News: Adocia (Euronext Paris: FR0011184241 – ADOC), a clinical-stage biopharmaceutical company focused on the research and development of innovative therapeutic solutions for the treatment of diabetes and obesity, reports financial results for the first quarter of 2024 and provides a business update. “We continue to pursue our priority of concluding a partnership with Sanofi on M1Pram as soon as possible”, declared Olivier Soula, CEO of Adocia. “At the